Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-Term Investments | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $33.8M | $7,697.0K | $6,782.1K | $40.2M | $101.5M | $139.0M | $312.8M | $310.7M | $283.5M | $272.3M | $270.7M | $269.9M | $220.2M | $192.7M | $246.2M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Long-Term Investments is $305.5M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Long-Term Investments growth was 46.9%. The average annual Long-Term Investments growth rates for Novo Nordisk A/S have been 3.5% over the past three years, 0.3% over the past five years.